Beam Therapeutics Inc. is a biotechnology company that develops precision genetic medicines for patients with serious diseases in the United States. Its hematology and genetic disease programs include Ristoglogene autogetemcel, an autologous hematopoietic stem cell therapy for sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle for severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for phenylketonuria; and BEAM-301, a liver-targeting LNP for glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene-edited HSCs, and BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. It has research collaborations with Pfizer Inc. on in vivo base editing for rare genetic diseases of the liver, muscle, and central nervous system; with Verve Therapeutics, Inc. for cardiovascular disease treatments; and with Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Cathie Wood's Ark Invest Adds to Meta, Airbnb and Beam Therapeutics Positions
Ark Invest founder and CEO Cathie Wood added to her funds' existing positions in Meta Platforms, Airbnb and Beam Therapeutics on Monday, disclosing the trades at the end of the trading day. Meta Platforms, parent of Facebook, Instagram and WhatsApp, jumped 11% on Monday, its biggest single-day gain in more than a year, and Wells Fargo raised its price target on the stock from $640 to $796 ahead of Meta Connect on Wednesday and Thursday. Airbnb is on track for its sixth consecutive year of double-digit revenue growth, though its shares remain 24% below the all-time highs reached in early 2021 shortly after its IPO. Beam Therapeutics fell 10% on Sept. 9 and nearly 20% over three trading days after updated Phase 1/2 data for its BEAM-302 candidate, a gene-editing treatment for alpha-1 antitrypsin deficiency, showed encouraging efficacy but less numerical improvement than investors expected; the U.S. Food and Drug Administration feedback has Beam pursuing an accelerated approval pathway. Beam shares are down 9% year-to-date.
Beam Therapeutics shares drop on updated trial data for gene-editing drug
Beam Therapeutics lost more than 10% on Tuesday after releasing updated Phase 1/2 trial data for BEAM-302, its gene-editing therapy for alpha-1 antitrypsin deficiency. The company reported that the treatment was well tolerated but noted elevations in liver enzymes, including alanine transaminase and aspartate aminotransferase. The data cut from June 24 covered the dose-escalation portion of the study, which tested doses up to 75 mg in Part A and Part B cohorts, but excluded the multi-dose cohort and Part A expansion cohort. One patient with underlying AATD-linked liver disease in Part B experienced a brief Grade 3 case of ALT/AST elevations after receiving 60 mg, the dose selected for an accelerated approval pathway. J.P. Morgan analyst Brian Cheng, who rates Beam Overweight, downplayed the safety event, saying it is not a major overhang but could affect perception of the drug's prospects. The company plans to expand the study globally, targeting 50 additional patients with AATD-associated lung disease, with dosing of this registrational cohort starting in July.
BEAM · Technology · Negative Updated Phase 1/2 data for BEAM-302 showed liver enzyme elevations including a Grade 3 ALT/AST case, raising safety concerns for the gene-editing therapy.
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
Beam Therapeutics Inc. has appointed Eric Foster as chief commercial officer, effective immediately, to lead its commercial organization as the company prepares for the potential launch of its lead candidate risto-cel in 2027. Foster brings over 25 years of commercial leadership, most recently as chief commercial officer at Ardelyx, and previously served as senior vice president and U.S. general manager at Amgen following its acquisition of Horizon Therapeutics, where he led franchises generating $2.75 billion in net sales. CEO John Evans highlighted Foster's track record in building high-performing commercial teams in rare disease markets, which will be crucial as Beam advances multiple product candidates across its hematology and genetic disease franchises. Foster holds a Bachelor of Arts in Economics from the University of Georgia and an MBA from Auburn University.
Beam Therapeutics Doses First Patient in Pivotal BEAM-302 Trial for AATD
Beam Therapeutics has dosed the first patient in the global pivotal cohort of its Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency. The company also completed dosing for all adult and adolescent patients in the Phase 1/2 BEACON trial of risto-cel in sickle cell disease, with a biologics license application submission expected as early as year-end 2026. Updated BEAM-302 clinical data were selected for a late-breaking oral presentation at the European Respiratory Society Congress in September 2026. Beam received FDA clearance of its investigational new drug application for BEAM-304 in phenylketonuria and has initiated clinical start-up activities. The company ended the second quarter of 2026 with $1.2 billion in cash, cash equivalents and marketable securities, and expects its cash runway to support operating plans into mid-2029.
ARK Invest buys $16.7M in SPCX shares, sells Deere and Twist Bioscience
ARK Invest purchased 122,807 shares of Space Exploration Technologies Corp for $16.7 million across several of its exchange-traded funds on Wednesday. The firm sold 6,833 shares of Deere & Co for nearly $4 million, extending a recent selling trend, and trimmed its position in Twist Bioscience Corp by selling 71,209 shares for $6,588,968. ARK's ARKG ETF increased its stake in Beam Therapeutics by acquiring 32,751 shares valued at $1,011,678, while the ARKK ETF sold 99,977 shares of 10X Genomics Inc for $4,577,946. Additionally, ARK invested in Kratos Defense and Security Solutions Inc, buying 34,123 shares across ARKQ and ARKX ETFs for a total of $1,718,434.
Prime Medicine Wins Arbitration Ruling on PM647 Gene-Editing Drug
Prime Medicine announced a positive, binding resolution to its arbitration with Beam Therapeutics over their 2019 Collaboration and License Agreement. The Tribunal declared that PM647, the company's investigational Prime Editing drug for Alpha-1 Antitrypsin Deficiency, falls within Prime Medicine's defined field under the agreement, meaning Prime Medicine did not breach the agreement and owes no monetary damages to Beam Therapeutics. PM647 uses a universal liver lipid nanoparticle to correct the E342K mutation in the SERPINA1 gene, the most common disease-causing mutation in AATD, and has shown high editing efficiency and restored healthy-range protein levels in fully humanized mouse models at clinically relevant doses.
Biotech & Genomic Medicine › Gene & Cell Editing Competition
PRME · Regulation · Positive Prime Medicine won binding arbitration, confirming PM647 is within its defined field and no breach or damages owed, removing legal uncertainty.
BEAM · Competition · Negative Beam Therapeutics lost arbitration to Prime Medicine, with tribunal ruling that PM647 falls within Prime's field and no damages owed, weakening Beam's competitive position.
Intellia Therapeutics Stock Surges 38% in a Month on Pipeline Progress
Intellia Therapeutics shares have surged 38% over the past month, outperforming the industry, sector, and S&P 500, driven by positive regulatory and clinical milestones for its lead candidate lonvoguran ziclumeran. The phase III HAELO study evaluating lonvoguran ziclumeran for hereditary angioedema met its primary endpoint and a key secondary endpoint in April 2026, and additional data in June 2026 showed an 89% reduction in monthly attacks requiring on-demand treatment and a 91% reduction in moderate-to-severe attacks compared with placebo. Intellia initiated a rolling biologics license application submission to the FDA in April 2026 and plans a commercial launch in the first half of 2027 upon potential approval. The company is also advancing nexiguran ziclumeran in two late-stage studies for ATTR amyloidosis after the FDA lifted a clinical hold earlier this year. Despite a premium valuation of 3.79 times trailing book value versus the industry's 3.69, the Zacks Consensus Estimate for 2026 loss per share has narrowed from $3.46 to $3.18 over the past 60 days, and the 2027 loss estimate has narrowed from $1.01 to 65 cents. Zacks rates the stock a Hold, citing pipeline promise and narrowing losses but noting competition from CRISPR Therapeutics and Beam Therapeutics and the lack of marketed products.
New CRISPR 'DNA Shredder' Could Expand Gene-Editing Market
A newly discovered CRISPR-based tool that destroys diseased cells by shredding their DNA is generating excitement in scientific circles, with potential long-term implications for gene-editing companies like CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics. Unlike traditional gene editing, this programmable cell-killing approach reads a signal unique to a diseased cell and cuts its DNA into fragments faster than the cell can repair, leading to cell death while sparing healthy cells. A May paper in Nature showed the therapy cutting lung cancer cell growth by about 50% in a lab dish, matching the chemotherapy drug cisplatin, and a June Nature paper extended the approach to target a gene mutated in 40% to 50% of all cancers. None of the major public CRISPR companies currently have this technology in their pipelines, though private German biotech Akribion Therapeutics is developing a program targeting HPV-positive head and neck cancer. The new papers significantly expand the addressable market for CRISPR-based medicine, and the incumbents may have an advantage due to their existing drug-delivery infrastructure.
FDA Clears Beam Therapeutics' IND for Gene-Editing Therapy BEAM-304
Beam Therapeutics shares rose 5% after the FDA cleared its investigational new drug application for BEAM-304, a gene-editing therapy for phenylketonuria. The clearance allows Beam to advance its liver-targeted lipid nanoparticle-based treatment designed to correct mutations in the PAH gene, potentially restoring normal phenylalanine metabolism. The company plans to begin a phase I/II open-label study initially in patients with the R408W mutation, assessing safety, tolerability, and blood phenylalanine reduction. Phenylketonuria affects approximately 20,000 people in the United States and currently has no approved curative treatments. Beam's stock has gained 23.2% year to date, outperforming the broader industry's 1% decline.
United States